All News
Surprising Link Between Weight Gain and RA Activity
d
MedPage Today
In patients with rheumatoid arthritis (RA) treated with infliximab (Remicade), increases in body mass index (BMI) scores over time were not associated with increased disease activity or faster radiographic progression.
Read Article
Tuesday 10/10--this webinar focuses on steroid use in #PMR. Join panelists Dr. Max Yates and Dr. Richard Conway. Moderated by Dr. David Liew.
https://t.co/4PefLrRoBx
@drmaxyates1 @richardpaconway @drdavidliew https://t.co/089UBUsJLj
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatologist SURVEY Question: How often do you start a new PMR patient on 20mg or more of prednisone? Answer here>> https://t.co/beYWFwK1LX
Links:
Dr. John Cush RheumNow ( View Tweet)
Sustained Efficacy of Bimekizumab in PsA
BE OPTIMAL trial tested the benefits of a dual IL-17 A/F inhibitor, BKZ, in patients with active PsA and showed superior efficacy over placebo, that was sustained beyond the primary endpoint, from week 16 to 52.
https://t.co/JQ53JV0dvv https://t.co/RQoIXsVnOr
Dr. John Cush RheumNow ( View Tweet)
SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica
NEJM reported today that #PMR patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo).
https://t.co/dC9Z7UgkcO https://t.co/44QEittlEX
Dr. John Cush RheumNow ( View Tweet)
2005 study of 364 PMR pts (age 73.4 yrs) - 284 Rx w/ steroids, predictors of relapse =higher initial CS dose & faster CS tapering. Relapse 4-fold higher when the CS tapering rate was fast (HR 4.27). Minimize initial CS dose and taper CS slowly!! https://t.co/hUpBO7fEgh https://t.co/fv9txM0BeH
Dr. John Cush RheumNow ( View Tweet)
Comparison of 354 527 COVID-19 infected vs 6.1 mill controls shows COVID incr risk of alopecia areata (aHR 1.12), alopecia totalis (aHR 1.74), ANCA vasculitis (aHR 2.76), Crohns (aHR), & sarcoidosis (aHR). https://t.co/enwb2taza4 https://t.co/ljY7uMPIrm
Dr. John Cush RheumNow ( View Tweet)
Epidemiology of idiopathic inflammatory myopathies:
- incidence 0.2 - 2 per 100,000 PYs
- prevalence 2 - 25 per 100,000
#s vary w/ age/gender & geography; BUT is still unreported in South America, Africa & Asia https://t.co/fRUNV75xQL
Dr. John Cush RheumNow ( View Tweet)
New download on #PMR available now!
https://t.co/esSuRBwSr0 https://t.co/7d2B2x63tF
Dr. John Cush RheumNow ( View Tweet)
Steroid Tapering in #PMR: What's the Gold Standard?
Dr. Anisha Dua, Chicago, discusses the gold standard tapering of glucocorticoids in polymyalgia rheumatica.
https://t.co/oXVrHuHE58 https://t.co/fHNXodtAeV
Dr. John Cush RheumNow ( View Tweet)
1 in 3 of our pts are on steroids; nice ARD full read review of important papers on steroids 2022-23 written by Prof J Bijlsma, covering:
Mechanisms of action
CV AE
Bone Effects
Infections, COVID-19
Clin trials
Benefit vs Harm
Tapering
GC Guidelines
https://t.co/LnqLk8eKgn https://t.co/5xfvic5YIX
Dr. John Cush RheumNow ( View Tweet)
Pneumothorax in an RA patient is likely from rheumatoid nodules eroding into air spaces in advanced seropositive RA patients. https://t.co/u9rQlKKNKd https://t.co/QKquUngAld https://t.co/e9B3Jx92BW
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/SSKz6RcR5r https://t.co/fLSNHazFS6 https://t.co/pvfrjkOeyW… https://t.co/ASihH17Phu
Links:
Dr. John Cush RheumNow ( View Tweet)
This Tuesday Night Rheumatology focuses on steroid use in #PMR. Join panelists Dr. Max Yates and Dr. Richard Conway. Moderated by Dr. David Liew.
https://t.co/swGbCcoEc9
@drmaxyates1 @richardpaconway @drdavidliew https://t.co/kZQ2wFbjt9
Links:
Dr. John Cush RheumNow ( View Tweet)
JAKi Safety and Efficacy in bDMARD-IR Patients with RA: Results Through 5 Years
Now in the RheumNow poster hall: Long-term extension outcomes from SELECT-BEYOND through 5 years in bDMARD-IR patients with RA. Sponsored by AbbVie US Medical Affairs.
https://t.co/xltJjADdHz https://t.co/sytZLayxDZ
Dr. John Cush RheumNow ( View Tweet)
Registration is now open! Early bird pricing is available until 11/30/23. See you there!
https://t.co/zEf9KTXYqX https://t.co/eQTQzgJpVF
Links:
Dr. John Cush RheumNow ( View Tweet)
The frequency of demyelinating Dz (DD) studied in 2260 #SpA pts, finging 18 DD events (IR 31 per 100K PYs) DD at 20 yrs was higher in axSpA than PsA (1.30 vs 0.13%, p= 0.01). DD risk w/ smoking (HR 2.9), axSpA (8.8) & IBD (5.7) -- NOT TNFi! https://t.co/IVoCxd6H0D https://t.co/FQtHuUWYUx
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Steroid Response for a #PMR Diagnosis
Featuring Dr. Jack Cush (Dallas, TX): Exquisite response to prednisone but other red flags!
https://t.co/DCtcZqG5NE https://t.co/Rs9rfds5w0
Dr. John Cush RheumNow ( View Tweet)
TNR: #PMR Diagnosis and Monitoring
Tuesday Night Rheumatology webinar on the diagnosis and monitoring of PMR.
Featuring Panelists, Drs. Claire Owen, Anisha Dua, Stephen Paget and moderated by Jack Cush.
https://t.co/7ewWLAUf4N
@anisha_dua @Rheummd @drceowen https://t.co/GCtYUHBPba
Dr. John Cush RheumNow ( View Tweet)
Multinational study of 47 studies of 11,085 #RA pts showed the prevalence of ANXIETY to range from 2.4% to 77%. Variance due to inconsistent, non-standardized self-report measures and clinical thresholds. Common; but how common? https://t.co/elcxjfSI7N https://t.co/iRNeQy4pEk
Dr. John Cush RheumNow ( View Tweet)